A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

计划入组 120 人 · 首次发布于 2024 年 4 月 12 日

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

计划入组 420 人 · 首次发布于 2025 年 5 月 20 日

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

计划入组 80 人 · 首次发布于 2024 年 7 月 26 日

SSGJ-707

SSGJ-709

SSGJ-705

PF PRISM C.V.

Netherlands

PF Consumer Healthcare Canada ULC

Canada

PF Consumer Healthcare B.V. (Puerto Rico Operations) LLC

United States

Sunshine Guojian Posts 95% Profit Surge as Two Autoimmune Antibodies Win NMPA Approval

Pfizer Accelerates PF-08634404 Bispecific Development with Multiple Phase 3 Trials Following $1.25B 3SBio Deal

Pfizer Enters $6 Billion Licensing Deal with China's 3SBio for Novel Cancer Drug